Reactivation of mTOR in acute kidney injury (AKI)
View Patent ↗The subject method described herein relates to a method of treating, preventing, or reducing the incidence of Acute Kidney Injury (AKI) in a subject in need thereof by administering to the subject a pharmaceutically effective amount of one or more amino acids.
1 . A method of treating, preventing, or reducing incidence of Acute Kidney Injury (AKI) in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of one or more amino acids, wherein the subject has disrupted mTOR signaling, and wherein the one or more amino acids is selected from leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, aspartic acid, or a combination thereof.
2 . The method of claim 1 , comprising administering to the subject the pharmaceutically effective amount of the one or more amino acids via infusion.
3 . The method of claim 1 , wherein before administration of the pharmaceutically effective amount of one or more amino acids, endocytosis is disrupted in a kidney of the subject.
4 . The method of claim 3 , wherein the disrupted endocytosis in the kidney is associated with the presence of altered Sphingolipid Transporter 1 (Spns1) activity in the subject.
5 . The method of claim 1 , wherein the AKI is Rhabdomyolysis (Rh)-induced AKI.
6 . The method of claim 1 , wherein the AKI is ischemic AKI (iAKI).
7 . The method of claim 6 , wherein the iAKI is ischemia-reperfusion (I/R)-induced iAKI.
8 . The method of claim 1 , wherein the AKI is Rh-induced AKI and the one or more amino acids is selected from isoleucine, threonine, arginine, valine, histidine, or a combination thereof.
9 . The method of claim 1 , wherein the AKI is I/R-induced iAKI and the one or more amino acids is selected from leucine, isoleucine, glutamine, threonine, histidine, aspartic acid, or a combination thereof.
10 . The method of claim 1 , wherein a level of serum creatinine (sCr) or a level of blood urea nitrogen (BUN) is decreased in the subject following the administration of the pharmaceutically effective amount of the one or more amino acids.
11 . The method of claim 1 , wherein the one or more amino acids is formulated with at least one excipient suitable for intravenous administration.
12 . A method of treating, preventing, or reducing a diminished kidney function or a renal failure in a subject in need thereof, the method comprising administering to the subject a pharmaceutically effective amount of one or more amino acids, wherein the diminished kidney function or renal failure of the subject is due to AKI and wherein the subject has disrupted mTOR signaling, and wherein the one or more amino acids is selected from leucine, isoleucine, threonine, histidine, valine, arginine, glutamine, aspartic acid, or a combination thereof.
13 . The method of claim 12 , comprising administering to the subject the pharmaceutically effective amount of the one or more amino acids via infusion.
14 . The method of claim 12 , wherein before administration of the pharmaceutically effective amount of one or more amino acids, endocytosis is disrupted in a kidney of the subject.
15 . The method of claim 14 , wherein the disrupted endocytosis in the kidney is associated with the presence of altered Sphingolipid Transporter 1 (Spns1) activity in the subject.
16 . The method of claim 12 , wherein the AKI is Rhabdomyolysis (Rh)-induced AKI.
17 . The method of claim 12 , wherein the AKI is ischemic AKI (iAKI).
18 . The method of claim 17 , wherein the iAKI is ischemia-reperfusion (I/R)-induced iAKI.
19 . The method of claim 12 , wherein the AKI is Rh-induced AKI and the one or more amino acids is selected from isoleucine, threonine, arginine, valine, histidine, or a combination thereof.
20 . The method of claim 12 , wherein the AKI is I/R-induced iAKI and the one or more amino acids is selected from leucine, isoleucine, glutamine, threonine, histidine, aspartic acid, or a combination thereof.
21 . The method of claim 12 , wherein a level of serum creatinine (sCr) or a level of blood urea nitrogen (BUN) is decreased in the subject following the administration of the pharmaceutically effective amount of the one or more amino acids.